Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 376
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 939.83k | 無 | 1952 |
Mr. Brian J. Lynch J.D. | Senior VP & General Counsel | 763.75k | 1.27M | 1962 |
Mr. Alex G. Howarth | Executive Officer | 757.26k | 無 | 1969 |
Mr. William J. Sibold | CEO, President & Director | 無 | 無 | 1966 |
Ms. Mardi C. Dier | CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP | 無 | 無 | 1964 |
Mr. Ronald Filippo | Chief Information Officer | 無 | 無 | 無 |
Ms. Tina E. Ventura | Chief Investor Relations Officer | 無 | 無 | 無 |
Dr. Kianoush Motesharei Ph.d. | Senior Vice President of Business & Corporate Development | 無 | 無 | 1970 |
Mr. Clint Wallace | Chief Human Resources Officer | 無 | 無 | 無 |
Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | 無 | 無 | 無 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
截至 2024年4月1日 止,Madrigal Pharmaceuticals, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中:3;董事會:9;股東權利:8;現金賠償:7。